OXGN - OXiGENE, Inc., a biotechnology company, develops small-molecule therapeutics to treat cancer and eye diseases. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. The company's lead clinical compound is Combretastatin A4P, which is being evaluated in multiple ongoing clinical trials in various oncology and ophthalmic indications, as a single-agent, as well as in combination with other therapies, including chemotherapy, radiotherapy, and antibody therapy against vascular endothelial growth factor activity. OXiGENE's Combretastatin A4P is undergoing a Phase II clinical trial to treat patients with platinum-resistant ovarian cancer in combination with carboplatin and paclitaxel; and a Phase Ib clinical trial to treat patients with advanced solid tumors in combination with the anti-angiogenic drug, Avastin. It also evaluates Combretastatin A4P to treat non-small cell lung cancer and cervical cancer. In addition, the company engages in clinical development of Combretastatin A4P for the treatment of myopic macular degeneration and wet age-related macular degeneration in the field of ophthalmology; and ortho-quinone prodrugs for indications in oncology. OXiGENE was founded in 1988 and is headquartered in Waltham, Massachusetts.
 |
